DeDe Sheel
Plus aucun poste en cours
Profil
DeDe Sheel worked as Director-Investor Relations & Communications at Anacor Pharmaceuticals LLC, Head-Investor Relations & Corporate Communications at Angiotech Pharmaceuticals, Inc., Vice President-Investor Relations at Sierra Oncology, Inc., Vice President-Investor Relations at Aurinia Pharmaceuticals, Inc., and Head-Investor Relations at Aimmune Therapeutics, Inc. He obtained an undergraduate degree from the University of California, Berkeley and an MBA from The Leonard N Stern School of Business.
Anciens postes connus de DeDe Sheel
| Sociétés | Poste | Fin |
|---|---|---|
| SIERRA ONCOLOGY, INC. | Investor Relations Contact | - |
| AURINIA PHARMACEUTICALS INC. | Investor Relations Contact | - |
| ANACOR PHARMACEUTICALS INC | Investor Relations Contact | - |
| AIMMUNE THERAPEUTICS, INC. | Investor Relations Contact | - |
Angiotech Pharmaceuticals, Inc.
 Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | Public Communications Contact | - |
Formation de DeDe Sheel
| University of California, Berkeley | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AURINIA PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
